Medical News

RSS

Study indicates pain treatment may vary in Latino and white children post surgery

Differences might exist in the amount of pain medicine given to Latino and white children after surgery, found a new, small study in which Latino children received 30 percent less opioid analgesics (morphine or morphine-like drugs) than white children did.

9 Feb 2010

Seven-day exercise plan for reducing cancer risk

Being active for at least 30 minutes every day reduces your risk of developing some types of cancer. Fitness experts at The University of Texas M. D. Anderson Cancer Center have designed an exclusive exercise plan based on this evidence that will fit into almost anyone's lifestyle.

9 Feb 2010

Phase 1 trial of Cerus' INTERCEPT red blood system meets primary endpoint

Cerus Corporation announced today that its Phase 1 trial of red blood cells treated with the INTERCEPT Blood System met its primary endpoint, with preliminary analysis demonstrating that greater than 75 percent of treated cells continued to circulate 24 hours following transfusion. The INTERCEPT red blood cell system is a pathogen inactivation treatment the company is developing to protect against transmission of infectious diseases through red blood cell transfusions. An estimated 70 million units of red blood cells are transfused worldwide each year.

9 Feb 2010

Journal highlights toxic nature of herbal medicines

A University of Adelaide forensic pathologist has sounded a worldwide warning of the potential lethal dangers of herbal medicines if taken in large quantities, injected, or combined with prescription drugs.

9 Feb 2010

Analysts: If health reform fails, expect more industry mergers

BusinessWeek: "With Congress' sweeping overhaul of the health system stalled, industry will seek its own answers to a push by government and the private sector to rein in costs, said Curtis Lane, senior managing director at MTS Health Partners, a New York-based equity fund."

9 Feb 2010

Boston researchers identify new mechanism that inhibit tumor growth in mice

A team of researchers, led by Pier Paolo Pandolfi, at Beth Israel Deaconess Medical Center, Boston, has identified a new type of cellular senescence (i.e., irreversible arrest of cell growth) and determined a way to enhance it to suppress prostate tumor development and growth in mice.

9 Feb 2010

Alnylam Pharmaceuticals receives 'Notice of Allowance' from USPTO

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has awarded a Notice of Allowance for the “Soutschek and Manoharan” patent (Application No. 10/916,185), which covers certain chemically modified siRNAs of any length directed to any target, including siRNAs with sterol conjugates for in vivo delivery.

9 Feb 2010

FDA approves Lupin Pharmaceuticals' Amlodipine/Benazepril capsules

Lupin Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (U.S. FDA) has granted final approval for its Amlodipine/Benazepril 2.5mg/10mg, 5mg/10mg, 5mg/20mg and 10mg/20mg capsules. Commercial shipments of the product have already commenced.

9 Feb 2010

Skilled Healthcare Group announces fourth-quarter and full-year 2009 results

Skilled Healthcare Group, Inc. today reported consolidated revenues for the year ended December 31, 2009 of $759.8 million, an increase of 3.6 percent compared to 2008. Consolidated revenues were $189.0 million for the three-month period ended December 31, 2009, compared to $189.8 million for the three-month period ended December 31, 2008.

9 Feb 2010

New revolutionary treatment for patients suffering from movement disorders

Deep Brain Stimulation (DBS), a new treatment being offered at Geisinger Medical Center (GMC) and Geisinger Wyoming Valley Medical Center (GWV), can dramatically reduce symptoms of movement disorders.

9 Feb 2010

GeoVax Labs provides updates on HIV-1 vaccine trials

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today provided an update on its vaccine trials progress.

9 Feb 2010

Study indicates women receiving antiretroviral therapy are more likely to become pregnant

In PLoS Medicine this week a study conducted in a multi-country HIV treatment program in sub-Saharan Africa has found that pregnancy rates increase in HIV-infected women after they start antiretroviral therapy (ART).

9 Feb 2010

Positive data from Cara Therapeutics' peripherally-restricted kappa opioid agonist Phase II trial

Cara Therapeutics, Inc. today announced positive data in a Phase II proof-of-concept clinical trial of its peripherally-restricted kappa opioid agonist, CR845. The 46 patient Phase II, multi-center, double-blind, placebo-controlled study was conducted at eight hospitals in the United States and evaluated the efficacy and safety of CR845 in women following laparoscopic-assisted hysterectomy.

9 Feb 2010

Biocell Center participates in ‘Society for Maternal-Fetal Medicine’ meeting

Biocell Center announced today its further commitment to working with maternal-fetal-medicine doctors by attending the Society for Maternal-Fetal Medicine's (SMFM) annual meeting.

9 Feb 2010

BD recalls certain lots of BD Q-Syte Luer Access Devices and BD Nexiva Closed IV Catheter Systems

BD (Becton, Dickinson and Company) has voluntarily executed a product recall of certain lots of BD Q-Syte™ Luer Access Devices and BD Nexiva™ Closed IV Catheter Systems. Use of the affected devices may cause an air embolism or leakage of blood and/or therapy, which may result in serious injury or death. This field corrective action included notification to customers worldwide by letter. Neither the costs anticipated with the recall, nor the impact on BD's business, are expected to be material.

From BD (Becton, Dickinson and Company) 9 Feb 2010

FDA approves Sagent Pharmaceuticals' labetalol HCl injection for severe hypertension

Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that it has received FDA approval of labetalol hydrochloride (HCl) injection, USP, commonly used to control severe hypertension. The product will be available in two vial sizes – 100 mg per 20 mL and 200 mg per 40 mL, multi-dose vials.

9 Feb 2010

Emerging Healthcare Solutions issues Term Sheet review to ThromboVision

Emerging Healthcare Solutions, Inc. announced today that management has formally delivered an actionable Term Sheet to ThromboVision for review and that follow up communications have been very favorable.

9 Feb 2010

State health policy developments: Doctor shortages, hospital taxes, California insurance crackdown

The Los Angeles Times: "At a time when nearly 7 million Californians are uninsured, state regulators are trying to rein in discount health and dental plans that officials say frequently overstate benefits, offer little if any savings and promise access to doctors who aren't part of the system. Some of the discounters fraudulently market themselves as insurance, while preying on the poor, the elderly and others who urgently need care, officials say. ... Plan executives bristle at such criticism. They say a few bad apples have tarnished an industry that offers reliable -- and relatively inexpensive -- services.

9 Feb 2010

Abbott seeks U.S. approval for HE4 assay to monitor recurrence/progression of epithelial ovarian cancer

A new diagnostic tool physicians can use to monitor patients for the most common form of ovarian cancer may soon be available in the United States. Abbott's ARCHITECT HE4 assay uses a simple blood test to help in monitoring for the recurrence or progression of epithelial ovarian cancer. If approved, this important immunoassay would be the first automated HE4 test available in the United States.

9 Feb 2010

Texas court case and Florida web site raise questions about effectiveness of physician oversight

A Texas court case reveals gaps in physician oversight, The New York Times reports. "It was beyond [Anne Mitchell's] conception that she would be indicted and threatened with 10 years in prison for doing what she knew a nurse must: inform state regulators that a doctor at her rural hospital was practicing bad medicine." Mitchell was first jailed in June and will stand trial this week for "misuse of official information, a third-degree felony in Texas," after reporting a physician for using unorthodox procedures - some of which went awry - and practicing in an operating room where he did not have privileges.

9 Feb 2010

Medical News

Study indicates pain treatment may vary in Latino and white children post surgery

Seven-day exercise plan for reducing cancer risk

Phase 1 trial of Cerus' INTERCEPT red blood system meets primary endpoint

Journal highlights toxic nature of herbal medicines

Analysts: If health reform fails, expect more industry mergers

Boston researchers identify new mechanism that inhibit tumor growth in mice

Alnylam Pharmaceuticals receives 'Notice of Allowance' from USPTO

FDA approves Lupin Pharmaceuticals' Amlodipine/Benazepril capsules

Skilled Healthcare Group announces fourth-quarter and full-year 2009 results

New revolutionary treatment for patients suffering from movement disorders

GeoVax Labs provides updates on HIV-1 vaccine trials

Study indicates women receiving antiretroviral therapy are more likely to become pregnant

Positive data from Cara Therapeutics' peripherally-restricted kappa opioid agonist Phase II trial

Biocell Center participates in ‘Society for Maternal-Fetal Medicine’ meeting

BD recalls certain lots of BD Q-Syte Luer Access Devices and BD Nexiva Closed IV Catheter Systems

FDA approves Sagent Pharmaceuticals' labetalol HCl injection for severe hypertension

Emerging Healthcare Solutions issues Term Sheet review to ThromboVision

State health policy developments: Doctor shortages, hospital taxes, California insurance crackdown

Abbott seeks U.S. approval for HE4 assay to monitor recurrence/progression of epithelial ovarian cancer

Texas court case and Florida web site raise questions about effectiveness of physician oversight

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News